CRSP CRISPR Therapeutics AG - Common Shares
$56.87
가격 · 8월 19, 2026
기준 재무 정보 8월 3, 2026
52주 범위
$44–$78
37% of range
애널리스트 평점
HOLD
29 analysts
목표 주가
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
순이익률
-16569.8%
CRISPR Therapeutics AG - Common Shares 정보 위키백과 회사 개요
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
더 보기
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
CRSP 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$56.87
시가총액
$5.45B
P/E (TTM)
-8.8
EPS (TTM)
$-6.47
매출 (TTM)
$4M
배당 수익률
—
ROE
-32.0%
부채/자본
—
52주 범위
$44 – $78
CRSP 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
잉여현금흐름
$-346M
2016-12-31
→
2025-12-31
마진
-16569.8%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
CRSP
동종업계 중앙값
P/E (TTM)
-8.8
—
P/S (TTM)
1553.7
56.3
P/B
2.8
3.0
Price / FCF (주가 / FCF)
-15.8
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
CRSP
동종업계 중앙값
Operating Margin (영업이익률)
-18933.7%
—
Net Profit Margin (순이익률)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
CRSP
동종업계 중앙값
Current Ratio (유동비율)
13.3
6.7
Quick Ratio (당좌 비율)
13.2
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
CRSP
동종업계 중앙값
Revenue YoY (매출 YoY)
-90.6%
—
Revenue CAGR 3Y (매출 CAGR 3년)
43.1%
—
Revenue CAGR 5Y (매출 CAGR 5년)
37.3%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
CRSP
동종업계 중앙값
CRSP 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
29 명의 애널리스트
- 적극 매수 6 20.7%
- 매수 11 37.9%
- 보유 12 41.4%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
18 명의 애널리스트 · 2026-08-15
중앙값
$80.00
지금
$56.87
저가
$44.00
고가
$291.00
중앙값 목표
$80.00
+40.7%
평균 목표
$87.56
+54.0%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.01%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.94 | $-1.22 | 0.28% |
| 2026년 3월 31일 | $-1.28 | $-1.25 | -0.03% |
| 2025년 12월 31일 | $-1.37 | $-1.18 | -0.19% |
| 2025년 9월 30일 | $-1.17 | $-1.29 | 0.12% |
| 2025년 6월 30일 | $-1.29 | $-1.45 | 0.16% |
| 2025년 3월 31일 | $-1.58 | $-1.28 | -0.30% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 15
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
대차대조표 25
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
현금 흐름 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
유동성 및 지급능력 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 10
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
손익계산서 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
대차대조표 25
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
현금 흐름 11
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
유동성 및 지급능력 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
효율성 2
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
가치 평가 (TTM) 10
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $4M | $37M | $371M | $1M | $915M |
| 영업이익률 % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| 순이익 | $-582M | $-366M | $-154M | $-650M | $378M |
| 희석 EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| 당좌 비율 | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $-346M | $-145M | $-270M | $-533M | $457M |
최신 뉴스 이 회사 관련 최근 헤드라인
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- CRISPR 치료제 주식이 비현실적으로 저렴하다 -- 분석가들이 437% 상승 가능성을 보고 있다
- 대형주 성장 주도 vs 소형주 성장 잠재력? VUG vs VBK
- 1명의 월스트리트 최고 분석가가 CRISPR Therapeutics가 두 배 이상 상승할 수 있다고 생각합니다. 주식을 닥치는 대로 사야 할까요?
- 주목할 만한 ETF 유출 감지 - ARKK, CRSP, TEM, HOOD
- 이 바이오테크는 전체 치료 영역을 재정의할 수 있는 파이프라인을 보유하고 있습니다.
- 캐시 우드, 저가 매수 나선다: 그녀가 방금 매수한 2가지 주식
- 이 바이오테크 주식이 백만장자 만들기 포지션을 구축할 최고의 기회인가?
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 573개의 제출자 · $3.3B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 89 (0 이전 분기 대비) | 47 (-13 이전 분기 대비) | 148 (-24 이전 분기 대비) | 145 (+21 이전 분기 대비) | +5.4M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| ARK Investment Management LLC | $515,999,631 | 9,460,939 | 15.58% | 주식 |
| Orbis Allan Gray Ltd | $296,334,582 | 5,433,344 | 8.95% | 주식 |
| Capital World Investors | $259,039,094 | 4,749,525 | 7.82% | 주식 |
| STATE STREET CORP | $235,703,664 | 4,321,666 | 7.12% | 주식 |
| GSK plc | $175,652,997 | 3,220,627 | 5.30% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $117,453,717 | 2,153,015 | 3.55% | 주식 |
| SR One Capital Management, LP | $111,194,134 | 2,038,763 | 3.36% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $108,459,389 | 1,988,621 | 3.27% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $93,848,832 | 1,720,734 | 2.83% | 주식 |
| Amova Asset Management Americas, Inc. | $93,762,487 | 1,720,097 | 2.83% | 주식 |
| EcoR1 Capital, LLC | $75,771,113 | 1,389,276 | 2.29% | 주식 |
| Capital International Investors | $69,178,918 | 1,268,407 | 2.09% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $64,457,935 | 1,181,847 | 1.95% | 주식 |
| NEA Management Company, LLC | $57,734,408 | 1,058,570 | 1.74% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57,694,430 | 1,057,837 | 1.74% | 주식 |
| FMR LLC | $53,577,751 | 982,357 | 1.62% | 주식 |
| D. E. Shaw & Co., Inc. | $48,748,506 | 893,812 | 1.47% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35,380,807 | 648,713 | 1.07% | 주식 |
| UBS Group AG | $32,419,612 | 594,419 | 0.98% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $31,089,982 | 570,040 | 0.94% | 주식 |
| VANGUARD GROUP INC | $27,714,225 | 528,494 | 0.84% | 주식 |
| CITADEL ADVISORS LLC | $25,404,514 | 465,796 | 0.77% | 주식 |
| BANK OF AMERICA CORP /DE/ | $23,509,740 | 431,055 | 0.71% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23,298,288 | 427,178 | 0.70% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $20,836,025 | 382,032 | 0.63% | 주식 |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20,833,789 | 381,991 | 0.63% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18,456,336 | 338,400 | 0.56% | 풋 옵션 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17,763,678 | 325,700 | 0.54% | 콜 옵션 |
| Logos Global Management LP | $16,362,000 | 300,000 | 0.49% | 주식 |
| CITADEL ADVISORS LLC | $15,822,054 | 290,100 | 0.48% | 풋 옵션 |
| Squarepoint Ops LLC | $15,641,472 | 286,789 | 0.47% | 주식 |
| NORGES BANK | $14,767,032 | 270,756 | 0.45% | 주식 |
| CITADEL ADVISORS LLC | $13,973,148 | 256,200 | 0.42% | 콜 옵션 |
| GOLDMAN SACHS GROUP INC | $12,748,193 | 233,740 | 0.38% | 주식 |
| JANE STREET GROUP, LLC | $12,566,016 | 230,400 | 0.38% | 콜 옵션 |
| PEAK6 LLC | $11,633,382 | 213,300 | 0.35% | 풋 옵션 |
| Swiss National Bank | $9,228,168 | 169,200 | 0.28% | 주식 |
| Susquehanna Portfolio Strategies, LLC | $8,945,978 | 164,026 | 0.27% | 주식 |
| TWO SIGMA ADVISERS, LP | $8,516,256 | 162,400 | 0.26% | 주식 |
| LPL Financial LLC | $8,376,280 | 153,581 | 0.25% | 주식 |
| Bank of New York Mellon Corp | $8,337,366 | 152,867 | 0.25% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $8,301,261 | 152,205 | 0.25% | 주식 |
| Versant Venture Management, LLC | $8,117,243 | 148,831 | 0.25% | 주식 |
| Pictet Asset Management Holding SA | $7,989,776 | 142,213 | 0.24% | 주식 |
| Life Cycle Investment Partners Ltd | $7,836,962 | 143,692 | 0.24% | 주식 |
| TD Asset Management Inc | $7,777,513 | 142,602 | 0.23% | 주식 |
| AMERICAN CENTURY COMPANIES INC | $7,606,257 | 139,462 | 0.23% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $7,230,750 | 132,577 | 0.22% | 주식 |
| RHUMBLINE ADVISERS | $6,627,197 | 121,511 | 0.20% | 주식 |
| SFE Investment Counsel | $6,229,434 | 16,700 | 0.19% | 풋 옵션 |
| Private Advisor Group, LLC | $6,060,980 | 111,129 | 0.18% | 주식 |
| EverSource Wealth Advisors, LLC | $6,032,669 | 110,610 | 0.18% | 주식 |
| CONGRESS ASSET MANAGEMENT CO | $5,969,567 | 109,453 | 0.18% | 주식 |
| BlackRock, Inc. | $5,937,061 | 108,857 | 0.18% | 주식 |
| D. E. Shaw & Co., Inc. | $5,901,228 | 108,200 | 0.18% | 콜 옵션 |
| Campbell & CO Investment Adviser LLC | $5,864,632 | 107,529 | 0.18% | 주식 |
| JANE STREET GROUP, LLC | $5,852,142 | 107,300 | 0.18% | 풋 옵션 |
| California Public Employees Retirement System | $5,599,567 | 102,669 | 0.17% | 주식 |
| CAPITAL INTERNATIONAL SARL | $5,521,521 | 101,238 | 0.17% | 주식 |
| Affinity Asset Advisors, LLC | $5,454,000 | 100,000 | 0.16% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $5,439,011 | 114,337 | 0.16% | 주식 |
| CLOUGH CAPITAL PARTNERS L P | $5,363,300 | 98,337 | 0.16% | 주식 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5,172,465 | 94,838 | 0.16% | 주식 |
| Slow Capital, Inc. | $5,066,439 | 92,894 | 0.15% | 주식 |
| CAPITAL FUND MANAGEMENT S.A. | $4,867,258 | 89,242 | 0.15% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4,815,606 | 101,232 | 0.15% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $4,720,437 | 86,550 | 0.14% | 주식 |
| GROUP ONE TRADING LLC | $4,638,082 | 85,040 | 0.14% | 주식 |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4,575,742 | 83,897 | 0.14% | 주식 |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4,502,113 | 82,547 | 0.14% | 주식 |
| Concurrent Investment Advisors, LLC | $4,497,728 | 82,467 | 0.14% | 주식 |
| WELLS FARGO & COMPANY/MN | $4,309,151 | 79,009 | 0.13% | 주식 |
| Fisher Asset Management, LLC | $4,251,957 | 77,960 | 0.13% | 주식 |
| Trexquant Investment LP | $4,225,268 | 77,471 | 0.13% | 주식 |
| COMMONWEALTH EQUITY SERVICES, LLC | $4,194,122 | 76,900 | 0.13% | 주식 |
| JONES FINANCIAL COMPANIES LLLP | $4,055,652 | 73,847 | 0.12% | 주식 |
| Man Group plc | $3,992,001 | 73,194 | 0.12% | 주식 |
| PEAK6 LLC | $3,834,162 | 70,300 | 0.12% | 콜 옵션 |
| ENVESTNET ASSET MANAGEMENT INC | $3,822,196 | 70,081 | 0.12% | 주식 |
| ALGERT GLOBAL LLC | $3,593,095 | 65,880 | 0.11% | 주식 |
| Walleye Trading LLC | $3,528,738 | 64,700 | 0.11% | 풋 옵션 |
| MILLENNIUM MANAGEMENT LLC | $3,146,958 | 57,700 | 0.10% | 콜 옵션 |
| CAPITAL INTERNATIONAL LTD /CA/ | $3,057,840 | 56,066 | 0.09% | 주식 |
| NOMURA HOLDINGS INC | $3,055,713 | 56,027 | 0.09% | 주식 |
| Rafferty Asset Management, LLC | $3,045,132 | 55,833 | 0.09% | 주식 |
| Green Alpha Advisors, LLC | $3,043,550 | 55,804 | 0.09% | 주식 |
| Walleye Trading LLC | $3,005,154 | 55,100 | 0.09% | 콜 옵션 |
| Caption Management, LLC | $2,999,700 | 55,000 | 0.09% | 콜 옵션 |
| MetLife Investment Management, LLC | $2,958,413 | 54,243 | 0.09% | 주식 |
| BENJAMIN EDWARDS INC | $2,956,845 | 54,216 | 0.09% | 주식 |
| Quantinno Capital Management LP | $2,869,349 | 52,610 | 0.09% | 주식 |
| Cetera Investment Advisers | $2,856,133 | 52,368 | 0.09% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,788,521 | 51,128 | 0.08% | 주식 |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | 콜 옵션 |
| CITIGROUP INC | $2,781,540 | 51,000 | 0.08% | 풋 옵션 |
| WOLVERINE ASSET MANAGEMENT LLC | $2,727,000 | 50,000 | 0.08% | 풋 옵션 |
| OSAIC HOLDINGS, INC. | $2,693,150 | 49,381 | 0.08% | 주식 |
| Privium Fund Management B.V. | $2,452,882 | 44,974 | 0.07% | 주식 |
| CANADA PENSION PLAN INVESTMENT BOARD | $2,394,306 | 43,900 | 0.07% | 주식 |
| TUDOR INVESTMENT CORP ET AL | $2,318,604 | 42,512 | 0.07% | 주식 |
회사 내부자 32 명의 내부자 · 12 임원 · 16 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 2026년 3월 20일 M | 255,501 | 0 | 9 | $-10,756,932 |
| Brendan Smith | Chief Financial Officer | 2023년 2월 18일 M | 5,072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 2021년 3월 11일 M | 1,891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 2025년 3월 20일 M | 10,544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 2022년 8월 16일 A | 26,797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 2026년 5월 29일 A | 19,357 | 1 | 2 | $-312,892 |
| James R. Kasinger | General Counsel and Secretary | 2026년 5월 29일 A | 94,308 | 0 | 5 | $-645,902 |
| Phuong Khanh Morrow | Chief Medical Officer | 2023년 10월 13일 A | 4,411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 2021년 12월 3일 M | 52,364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 2018년 1월 16일 M | 25,204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 2017년 6월 15일 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 2016년 10월 24일 C | 505,617 | 0 | 0 | $0 |
| Christian Rommel | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Douglas A Treco | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Briggs Morrison | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Katherine A High | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Ali Behbahani | 이사 | 2026년 6월 5일 A | 14 | 0 | 0 | $0 |
| John Greene | 이사 | 2026년 6월 5일 A | 7,000 | 0 | 0 | $0 |
| Simeon George | 이사 | 2026년 6월 5일 A | 1,730,179 | 0 | 0 | $0 |
| Maria Fardis | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | 이사 | 2026년 6월 5일 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | 이사 | 2022년 6월 9일 A | 148,831 | 0 | 0 | $0 |
| Pablo J Cagnoni | 이사 | 2019년 11월 19일 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | 이사 | 2018년 12월 18일 S | 1,171,268 | 0 | 0 | $0 |
| Thomas Woiwode | 이사 | 2018년 6월 15일 A | 640,014 | 0 | 0 | $0 |
| Anthony N Coles | 이사 | 2017년 5월 31일 A | 70,000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% 소유주 | 2017년 12월 4일 S | 3,722,534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% 소유주 | 2016년 10월 24일 C | 744,380 | 0 | 0 | $0 |
| GSK plc | 10% 소유주 | 2016년 10월 24일 C | 3,220,627 | 0 | 0 | $0 |
| Raju Prasad | — | 2026년 8월 7일 G | 14,815 | 0 | 10 | $-5,100,841 |
| Rodger Novak | — | 2021년 6월 30일 S | 573,007 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 6 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 제출 서류 | 2021년 2월 16일 | — | 최초 제출 | — | SEC |
| GlaxoSmithKline plc ×5 제출 서류 | 2020년 7월 10일 | — | 최초 제출 | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 제출 서류 | 2020년 2월 4일 | — | 최초 제출 | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 제출 서류 | 2019년 6월 7일 | — | 최초 제출 | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 제출 서류 | 2018년 2월 8일 | — | 최초 제출 | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 제출 서류 | 2018년 1월 16일 | — | 최초 제출 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 32 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| GNOM · Global X Funds | 3.85% | 38,191 NS | 2026년 5월 31일 | N-PORT |
| IDNA · iShares Trust | 1.63% | 62,247 SH | 2026년 8월 8일 | 일간 |
| LABU · Direxion Shares ETF Trust | 0.98% | 97,235 NS | 2026년 4월 30일 | N-PORT |
| IBB · iShares Trust | 0.36% | 658,537 SH | 2026년 8월 8일 | 일간 |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.35% | 5,248 SH | 2026년 8월 8일 | 일간 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70,696 SH | 2026년 8월 8일 | 일간 |
| IWN · iShares Trust | 0.27% | 752,223 SH | 2026년 8월 8일 | 일간 |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.21% | 104,016 NS | 2026년 5월 31일 | N-PORT |
| ISCV · iShares Trust | 0.15% | 20,568 SH | 2026년 8월 8일 | 일간 |
| IWM · iShares Trust | 0.15% | 2,353,025 SH | 2026년 8월 8일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536,446 SH | 2026년 8월 8일 | 일간 |
| RSSL · Global X Funds | 0.15% | 39,589 NS | 2026년 4월 30일 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.10% | 6,636 SH | 2026년 8월 8일 | 일간 |
| ISCB · iShares Trust | 0.07% | 4,136 SH | 2026년 8월 8일 | 일간 |
| SMLF · iShares Trust | 0.07% | 57,970 SH | 2026년 8월 8일 | 일간 |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1,106,455 SH | 2026년 8월 8일 | 일간 |
| ESML · iShares Trust | 0.06% | 33,283 SH | 2026년 8월 8일 | 일간 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.06% | 108 NS | 2026년 5월 31일 | N-PORT |
| WSML · iShares Trust | 0.04% | 5,486 SH | 2026년 8월 8일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13,170 SH | 2026년 8월 8일 | 일간 |
| IWO · iShares Trust | 0.04% | 109,974 SH | 2026년 8월 8일 | 일간 |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.03% | 1,736 SH | 2026년 8월 8일 | 일간 |
| XT · iShares Trust | 0.03% | 21,837 SH | 2026년 8월 8일 | 일간 |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.03% | 3,509 NS | 2026년 5월 31일 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7,774 SH | 2026년 8월 8일 | 일간 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20,627 SH | 2026년 8월 8일 | 일간 |
| IYY · iShares Trust | 0.01% | 4,231 SH | 2026년 8월 8일 | 일간 |
| ITOT · iShares Trust | 0.01% | 128,511 SH | 2026년 8월 8일 | 일간 |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.01% | 15,609 NS | 2026년 5월 31일 | N-PORT |
| IWV · iShares Trust | 0.01% | 25,457 SH | 2026년 8월 8일 | 일간 |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 289 NS | 2026년 5월 31일 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 75,392 SH | 2026년 8월 8일 | 일간 |